Quick Answer
TENAX THERAPEUTICS, INC. reported Operating Income Loss of -$56.39 million for the year ending 2025.
- TENAX THERAPEUTICS, INC. showed a decrease of -189.2% in Operating Income Loss from 2024 to 2025.
- This data is from TENAX THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), TENAX THERAPEUTICS, INC.'s Operating Income Loss has declined by 633.8%.
- Historical annual values: Fiscal year 2025: -$56.39 million | Fiscal year 2024: -$19.49 million | Fiscal year 2023: -$8.23 million | Fiscal year 2022: $11.05 million | Fiscal year 2021: -$32.73 million | Fiscal year 2020: $9.87 million | Fiscal year 2019: -$8.56 million | Fiscal year 2018: -$6.89 million | Fiscal year 2017: -$9.21 million | Fiscal year 2016: -$52.65 million | Fiscal year 2015: -$14.82 million | Fiscal year 2014: -$16.61 million | Fiscal year 2013: -$5.19 million | Fiscal year 2012: -$8.22 million | Fiscal year 2011: $10.56 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: